Vertex Pharmaceuticals Incorporated Other Current Liabilities

Vertex Pharmaceuticals Incorporated (VX1.DE) currently reports a other current liabilities of $290M as of September 2026. That compares with $440M in the prior-year period — down 33.6% year over year. Use the charts on this page to explore Vertex Pharmaceuticals Incorporated's other current liabilities history and peer comparisons.

Vertex Pharmaceuticals Incorporated's other current liabilities decreased from $440M to $290M — a 33.6% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Vertex Pharmaceuticals Incorporated reported $290M in other current liabilities as of September 2026. That compares with $440M in the prior-year period — down 33.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $290M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Vertex Pharmaceuticals Incorporated, and consider following VX1.DE for alerts when major investors trade the stock.

Vertex Pharmaceuticals Incorporated is classified in the Healthcare sector. On other current liabilities, it currently shows $290M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VX1.DE with unrelated industries.